Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 23;9(12):e1217. doi: 10.1002/cti2.1217

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Cytokine levels in the supernatants of PBMCs from SARS‐CoV‐2 patients. (a) Cytokine levels detected after stimulation by the MNS mix or in the negative control (medium). P‐values are from the Wilcoxon test. (b) Cytokine levels detected after stimulation by the MNS mix, according to the severity of the disease in mild (n = 16), moderate (n = 6) and severe patients (n = 16). P‐values are calculated using partial Spearman’s rank correlation coefficients with severity status, adjusted for time from symptom onset to sampling. Comparisons between severe and mild patients using Dunn’s tests (post hoc for the Kruskal–Wallis test) are indicated as *P ≤ 0.05 or **P ≤ 0.01.